Baidu
map

Br J Dermatol:增强角质层脂质结构可改善成人干燥、易患湿疹皮肤的皮肤屏障功能并保护其免受刺激

2022-01-05 医路坦克 MedSci原创

特应性皮炎(AD)患者的皮肤以角质层(SC)脂质水平异常为特征。因此,板层基质被破坏,皮肤屏障功能减弱,增加了皮肤对刺激物和过敏原的敏感性。

    特应性皮炎(AD)患者的皮肤以角质层(SC)脂质水平异常为特征。因此,板层基质被破坏,皮肤屏障功能减弱,增加了皮肤对刺激物和过敏原的敏感性。

    皮肤屏障(SB)是一种物理渗透屏障,可以防止水分流失,保护身体免受外部环境的影响。它是由角质层(SC)形成的,角质层是一种防御结构,由交织在内部的角质细胞组成复杂的脂质混合物(脂层)。这些脂质包括等摩尔浓度的胆固醇、神经酰胺和游离脂肪酸,排列在多层膜中。脂膜的组成和结构对通透性屏障功能至关重要。

    在特应性皮炎/湿疹(AD)中,SC的脂质组成发生了显著的变化,包括神经酰胺EOS、EOH和NP的水平降低,物种水平的神经酰胺增加,亚种水平的神经酰胺普遍转向短链神经酰胺。这些变化导致脂层和角质细胞脂质包膜的缺陷形成,并被发现与干燥症有关。皮肤表面脂质的减少,特别是关键神经酰胺的减少,这些变化导致脂层和角质细胞脂质包膜的缺陷形成,并被发现与干燥症有关。皮肤表面脂质的减少,特别是关键神经酰胺的减少。这些变化导致脂质层和角质细胞脂质包膜的缺陷形成,并被发现与干燥有关。皮肤表面脂质的减少,特别是关键神经酰胺,而且可能与皮肤干燥的发病率增加有关。

     局部补充生理脂质是支持健康皮肤的潜在重要机制。然而,目前还不清楚局部使用的脂质是否能够进入脂质基质,并带来改变通透性屏障功能的结构变化。这项研究的目的是比较在多泡乳液中含有皮肤脂质(神经酰胺、甘油三酯和胆固醇)和保湿剂的保湿霜(测试霜)与参考润肤霜(不含这些添加剂)对干燥、易患湿疹的皮肤的SB结构的影响。在此之前,我们曾证明测试霜可在24小时内提供持续保湿。我们假设,皮肤脂质和保湿剂的受控释放将支持最佳的SB结构和功能,从而防止干燥和刺激。

     确定多泡乳剂中含有神经酰胺、甘油三酯和胆固醇的乳膏是否能增强皮肤屏障,防止皮肤刺激。

     对34例干燥、易患湿疹的成人进行了一项随机观察者盲法受试者内对照研究。每个参与者都接受了4周的治疗,一边是前臂和小腿上的测试膏,另一边是参考润肤膏。治疗前后分别测定皮肤性质。使用一种新的界面,用FTIR光谱分析了脂质结构。

     试验乳膏处理部位的皮肤屏障完整性更强(效果尺寸-161.9,95%CI-205.5,-118.3),皮肤对十二烷基硫酸钠的敏感度降低(-0.5点[97.57%CI-1.00,-0.25%]视觉红度和-15.34g/m2/h[95%CI-20.28,10.40]TEWL)与参照物相比,皮肤对月桂基硫酸钠的敏感度降低(-0.5点[97.57%CI-1.00,-0.25%]视觉红度和-15.34g/m2/h[95%CI-20.28,10.40]TEWL)。用测试乳膏处理的部位显示脂链有序性增强,这与皮肤屏障完整性显著相关(r0.606)。与对照相比,使用测试乳膏的治疗增加了水合作用(8.61电容单位,95%可信区间6.61到10.60),并减少了干燥的迹象。

   通过增强SC的脂质结构,4周的测试霜治疗促进了SB功能的改善,从而提供了对皮肤刺激的保护。与通常处方的润肤剂相比,测试霜带来了更好的皮肤保湿水平,更有效地减少了皮肤干燥的迹象。这一结果对临床实践具有重要的意义,因为简单的润肤霜非常普遍地用于干燥性皮肤状况的管理。研究表明,目前很少有患者和照顾者认为他们可以充分管理AD症状,包括慢性皮肤干燥和炎性病变的倾向。

   考虑到像SLS这样的刺激物是AD皮损的重要诱因,测试霜对SB的影响可能有助于保持皮肤健康,并减轻管理这种情况的负担。在局部皮质类固醇治疗的基础上添加测试乳膏可以帮助改善轻中度AD的预后。

 

文献来源: Danby SG,  Andrew PV,  Kay LJ,Enhancement of stratum corneum lipid structure improves skin barrier function and protects against irritation in adults with dry, eczema-prone, skin,Br J Dermatol 2021 Dec 18;

 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1688712, encodeId=ebe51688e12c7, content=<a href='/topic/show?id=df07e202459' target=_blank style='color:#2F92EE;'>#皮肤屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72024, encryptionId=df07e202459, topicName=皮肤屏障)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f1528615202, createdName=644982816_68283330, createdTime=Sun Jul 03 05:43:41 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022475, encodeId=71e220224e5ca, content=<a href='/topic/show?id=5b4d4e717dd' target=_blank style='color:#2F92EE;'>#屏障功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47717, encryptionId=5b4d4e717dd, topicName=屏障功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72bf2500198, createdName=小小小向日葵, createdTime=Tue May 24 02:43:41 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181096, encodeId=b5191181096f8, content=卖药来了, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/16/0faa103465b91b9063acb537ef1b1b3d.jpg, createdBy=a2fe5280621, createdName=默拜岐黄, createdTime=Wed Jan 05 22:58:04 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180944, encodeId=aedb1180944ad, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6d5619254, createdName=ms1000000413528422, createdTime=Wed Jan 05 17:07:18 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180801, encodeId=b85c118080148, content=明了, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abee5571249, createdName=奔袭, createdTime=Wed Jan 05 10:13:01 CST 2022, time=2022-01-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1688712, encodeId=ebe51688e12c7, content=<a href='/topic/show?id=df07e202459' target=_blank style='color:#2F92EE;'>#皮肤屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72024, encryptionId=df07e202459, topicName=皮肤屏障)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f1528615202, createdName=644982816_68283330, createdTime=Sun Jul 03 05:43:41 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022475, encodeId=71e220224e5ca, content=<a href='/topic/show?id=5b4d4e717dd' target=_blank style='color:#2F92EE;'>#屏障功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47717, encryptionId=5b4d4e717dd, topicName=屏障功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72bf2500198, createdName=小小小向日葵, createdTime=Tue May 24 02:43:41 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181096, encodeId=b5191181096f8, content=卖药来了, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/16/0faa103465b91b9063acb537ef1b1b3d.jpg, createdBy=a2fe5280621, createdName=默拜岐黄, createdTime=Wed Jan 05 22:58:04 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180944, encodeId=aedb1180944ad, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6d5619254, createdName=ms1000000413528422, createdTime=Wed Jan 05 17:07:18 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180801, encodeId=b85c118080148, content=明了, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abee5571249, createdName=奔袭, createdTime=Wed Jan 05 10:13:01 CST 2022, time=2022-01-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1688712, encodeId=ebe51688e12c7, content=<a href='/topic/show?id=df07e202459' target=_blank style='color:#2F92EE;'>#皮肤屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72024, encryptionId=df07e202459, topicName=皮肤屏障)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f1528615202, createdName=644982816_68283330, createdTime=Sun Jul 03 05:43:41 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022475, encodeId=71e220224e5ca, content=<a href='/topic/show?id=5b4d4e717dd' target=_blank style='color:#2F92EE;'>#屏障功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47717, encryptionId=5b4d4e717dd, topicName=屏障功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72bf2500198, createdName=小小小向日葵, createdTime=Tue May 24 02:43:41 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181096, encodeId=b5191181096f8, content=卖药来了, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/16/0faa103465b91b9063acb537ef1b1b3d.jpg, createdBy=a2fe5280621, createdName=默拜岐黄, createdTime=Wed Jan 05 22:58:04 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180944, encodeId=aedb1180944ad, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6d5619254, createdName=ms1000000413528422, createdTime=Wed Jan 05 17:07:18 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180801, encodeId=b85c118080148, content=明了, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abee5571249, createdName=奔袭, createdTime=Wed Jan 05 10:13:01 CST 2022, time=2022-01-05, status=1, ipAttribution=)]
    2022-01-05 默拜岐黄

    卖药来了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1688712, encodeId=ebe51688e12c7, content=<a href='/topic/show?id=df07e202459' target=_blank style='color:#2F92EE;'>#皮肤屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72024, encryptionId=df07e202459, topicName=皮肤屏障)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f1528615202, createdName=644982816_68283330, createdTime=Sun Jul 03 05:43:41 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022475, encodeId=71e220224e5ca, content=<a href='/topic/show?id=5b4d4e717dd' target=_blank style='color:#2F92EE;'>#屏障功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47717, encryptionId=5b4d4e717dd, topicName=屏障功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72bf2500198, createdName=小小小向日葵, createdTime=Tue May 24 02:43:41 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181096, encodeId=b5191181096f8, content=卖药来了, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/16/0faa103465b91b9063acb537ef1b1b3d.jpg, createdBy=a2fe5280621, createdName=默拜岐黄, createdTime=Wed Jan 05 22:58:04 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180944, encodeId=aedb1180944ad, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6d5619254, createdName=ms1000000413528422, createdTime=Wed Jan 05 17:07:18 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180801, encodeId=b85c118080148, content=明了, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abee5571249, createdName=奔袭, createdTime=Wed Jan 05 10:13:01 CST 2022, time=2022-01-05, status=1, ipAttribution=)]
    2022-01-05 ms1000000413528422

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1688712, encodeId=ebe51688e12c7, content=<a href='/topic/show?id=df07e202459' target=_blank style='color:#2F92EE;'>#皮肤屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72024, encryptionId=df07e202459, topicName=皮肤屏障)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f1528615202, createdName=644982816_68283330, createdTime=Sun Jul 03 05:43:41 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022475, encodeId=71e220224e5ca, content=<a href='/topic/show?id=5b4d4e717dd' target=_blank style='color:#2F92EE;'>#屏障功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47717, encryptionId=5b4d4e717dd, topicName=屏障功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72bf2500198, createdName=小小小向日葵, createdTime=Tue May 24 02:43:41 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181096, encodeId=b5191181096f8, content=卖药来了, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/16/0faa103465b91b9063acb537ef1b1b3d.jpg, createdBy=a2fe5280621, createdName=默拜岐黄, createdTime=Wed Jan 05 22:58:04 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180944, encodeId=aedb1180944ad, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6d5619254, createdName=ms1000000413528422, createdTime=Wed Jan 05 17:07:18 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180801, encodeId=b85c118080148, content=明了, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abee5571249, createdName=奔袭, createdTime=Wed Jan 05 10:13:01 CST 2022, time=2022-01-05, status=1, ipAttribution=)]
    2022-01-05 奔袭

    明了

    0

相关资讯

宝宝有湿疹,一定要忌口,不能洗澡,更不能用激素!这是真的吗?

门诊时常遇到爸爸妈妈带着几个月大的小宝宝来看湿疹,小宝宝瘙痒难耐、啼哭不止,病情反复发作、迁延难愈。

Br J Dermatol:极易误诊的婴儿湿疹和特应性皮炎

作为皮肤科医生,我们深知湿疹和特应性皮炎(AD)这两个术语在日常临床实践中经常互换使用,AD的准确分类对流行病学研究具有重要意义,

湿疹滥用激素药,婴儿惨变“大头娃娃”!缓解儿童湿疹别依赖激素药,维生素D或管用!

近日“老爸评测”曝光了一则“湿疹宝宝用含激素药膏,导致婴儿变‘大头娃娃’”的新闻,令网友们痛心不已。

JAAD:湿疹系统治疗的网络荟萃分析

这篇Cochrane综述不能直接比较传统和新的系统疗法治疗中度重度湿疹的有效性和安全性,但它能够对所有可用的生物制品进行排名。总体而言,dupilumab的研究结果与其他分析的结果是一致的

孩子湿疹反复发作,可能是特应性皮炎,护理时要注意这些……

孩子总是在面颊、四肢关节处、躯干、眼睑、耳廓、耳后等部位反反复复地起湿疹,还特别的痒。为什么孩子容易长湿疹?孩子长湿疹该怎么护理?

Clin Exp Allergy:湿疹发展竟然还与性别相关?

湿疹是一种常见的慢性炎症性皮肤病,结果表明,男性和女性可能经历不同的湿疹病程和不同的危险因素。

Baidu
map
Baidu
map
Baidu
map